Biotechnology News
Cutting edge news about companies engaged in the research and development of new drugs, medical devices and procedures as well as research, books and information on FDA approvals, patents and awards. Biotechnology news highlights the use of biological processes, organisms or systems to manufacture products that improve the quality of life.
NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program
On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022 - NuvOx Pharma
Timothy Healey Joins the Board of Director at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics, Inc.
NuvOx to Participate in the BIO CEO Investor Conference
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022 - NuvOx Pharma
FOXG1 Research Foundation’s Hourinaz Behesti PhD to Present at BIO CEO & Investor Conference 2022
The FOXG1 Research Foundation, the rare disease patient organization that is driving the science to find treatments for FOXG1 syndrome, will be presenting at the BIO CEO & Conference on February 14 to discuss Tapping into Therapeutic Development for Rare CNS Disorders. Dir. of Science, Hourinaz Behesti will discuss why FOXG1 is a viable target for biotech investment, and the suite of assets that the FRF has developed and characterized to help accelerate drug development. - February 09, 2022 - FOXG1 Research Foundation
ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit
ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics, Inc.
Optimoz Awarded GSA Cloud Services SIN
Optimoz, a leading provider of Cloud Engineering, Digital Transformation, Health IT and Blockchain solutions, announced today that it has been awarded Cloud and Cloud-Related Professional Services SIN 518210C under GSA Multiple Award Schedule (MAS). Optimoz’s services under the Cloud SIN... - February 04, 2022 - Optimoz, Inc.
Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics, Inc.
Decarbitation Inc. Product Launch: New Cannabis Crude Oil Decarboxylation Technology Using Controlled Cavitation
DecarbitationTM will be launching its website as well brand new 2 and 25 gallon systems for the decarboxylation of cannabis on February 2, 2022. - February 01, 2022 - Decarbitation Inc.
Thrombolex, Inc. – BASHIR™ Endovascular Catheters Show Dramatic Reduction in Thromboembolic Occlusions
Thrombolex, Inc. – BASHIR™ Endovascular Catheters Show Dramatic Reduction in Thromboembolic Occlusions in Segmental Pulmonary Arteries of Patients with Acute Intermediate Risk PE: Interim Results of NIH-Funded RESCUE Trial - January 17, 2022 - Thrombolex, Inc.
NuvOx to Present at Various Bio Forums in JPM Week
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022 - NuvOx Pharma
LifeTein Awarded the Fastest Peptide Synthesis Service in 2021
LifeTein was awarded the fastest peptide synthesis service in 2021 by New world Report, thanks to their speedy custom protein, antibody, and chemical services for biotech, pharma, academia, government customers, and diagnostics. Their services reach across the entire United States and more than 30 other nations. LifeTein provides the fastest turnaround time and most reliable quality in the industry, using their proprietary microwave-assisted heating technology for peptide synthesis. - January 07, 2022 - LifeTein
PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply
PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its spring 2022 cohort with the theme, “Digital Innovations in Neurological Disease.” - January 04, 2022 - PharmStars
Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI
Vesalio Initiates Clinical Study Evaluating Innovative Thrombectomy Technique for Patients with STEMI. - December 23, 2021 - Vesalio
Clicks and Bricks Announces Interview with Debra Crystal from Epigenetic Scan
Clicks and Bricks announces episode 111 of their podcast, an interview with Debra Crystal with Epigenetic Scan. - December 23, 2021 - Clicks and Bricks Podcast
Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round
This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. - December 09, 2021 - Mirror Biologics, Inc.
PharmStars Announces 2021 Accelerator Graduates
12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program. - December 08, 2021 - PharmStars
Doubling Down: HCPA Panel Selects Locus Performance Ingredients for Two Innovation Awards at XPAND2021
Green Tech Start-Up Recognized for Advancing Sustainable Cleaning Products with High-Performance Biosurfactant Ingredients and Carbon-Neutral Production Process. - December 08, 2021 - Locus Performance Ingredients
JVCKENWOOD to Sell 3D Cell Culture Multi-Well Plate for Drug Discovery Through Marketing Alliance with HCS Pharma
JVCKENWOOD Corporation ("JVCKENWOOD") has concluded a marketing alliance with HCS Pharma ("HCS"), a French start-up company, to sell multi-well plates for 3D cell culture in Japan and some parts of Asia that contribute to the drug discovery. - December 02, 2021 - HCS Pharma
Pelvic Floor HIFEM (Emsella) Improves the Intensity and Duration of Male Orgasm
Dr. Judson Brandeis studied the Emsella, a device that has been FDA-approved for the treatment of urinary incontinence by stimulating the pelvic floor muscles, in mid-life men with weak or delayed ejaculation. He discovered that four weekly thirty-minute treatments with the Emsella protocol 2 was enough to improve the self-reported intensity and duration of ejaculation. - November 30, 2021 - BrandeisMD
Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201
Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function,... - November 29, 2021 - Parvus Therapeutics U.S., Inc.
Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles
Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. - November 19, 2021 - Parvus Therapeutics U.S., Inc.
PharmStars Announces Showcase Event for Inaugural Class
PharmStars, a pharma-focused accelerator for digital health startups, announces the start of its 2021 Showcase Event. At the Showcase Event, the 12 startups in the accelerator’s current cohort will pitch their digital health solutions to PharmStars’ pharma members. The startups and pharma members will also have the opportunity to meet privately to discuss potential partnership opportunities. - November 17, 2021 - PharmStars
Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease
Mirror Biologics, Inc., a private clinical stage biopharmaceutical company, today announces the issuance of US Patent No. 11,160,852, “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of therapeutic vaccines against cancers and infectious... - November 17, 2021 - Mirror Biologics, Inc.
Exclusive Interview with Sriman Banerjee, Head of Packaging Development & CDE, Takeda
SMi Reports: An exclusive interview with Sriman Banerjee, Head of Packaging and Development & CDE, Takeda in preparation for his speaking slot at the 14th Annual Pre-filled Syringes Conference. - November 13, 2021 - SAE Media Group
Genetically Steady and Cost-Effective Gene Knockout Stable Cell Lines Products at Creative Biogene
Creative Biogene creatively develops a series of genetically steady and cost-effective gene knockout stable cell lines products for domestic and overseas clients. - November 06, 2021 - Creative Biogene
Eyecheck Announces FDA IND Clearance of STRI Formula, the First-Ever Food-Based, Combination Product in the STRI Phase 2 Clinical Trial for COVID-19 Symptoms
Eyecheck intends to initiate the Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial to evaluate STRI Formula in non-hospitalized adults with COVID-19. This trial is expected to begin in November 2021. - November 04, 2021 - Eyecheck, Inc.
PharmStars Welcomes Sumitovant Biopharma as Its Newest Member
PharmStars, the only pharma-focused, member-based accelerator for digital health startups, is pleased to announce that Sumitovant Biopharma has become its newest pharma member, joining existing members including Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk. PharmStars focuses on bridging the "pharma-startup gap." PharmStars provides startups with education and mentoring to help them engage with pharma as clients and partners. - November 03, 2021 - PharmStars
Creative Biogene Offers One-Stop Customized CRISPR-Based Microbe Genome Editing Service
CRISPR Platform is a mature system developed by Creative Biogene. Services like microbe’s gene knockout and gene knock-in central to the gene-editing area can be precisely performed based on the CRISPR platform. As a popular and useful tool in microbe genome editing, the CRISPR platform always presents excellent performance and serves quality-guaranteed results in a wide range of projects. - November 03, 2021 - Creative Biogene
Cord for Life®, Inc. Announces Cord Blood Clinical Trial Phase I Trial for the Treatment of Lower Back Pain of the Sacroiliac Joint
Cord for Life®, a full-service cord blood bank with over 25 years of experience, today announced plans to conduct a clinical trial to treat lower back pain arising from the Sacroiliac Joint (SIJ) using a biological therapeutic derived from umbilical cord blood. The company has received FDA... - October 29, 2021 - Cord For Life
Pascal Biosciences Announces Financing
Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF) is pleased to announce a non-brokered private placement financing of up to 9,000,000 units (each a “Unit”) of securities at a price of $0.10 per Unit for aggregate gross proceeds of up to $900,000.00 (the “Offering”). - October 29, 2021 - Pascal Biosciences
J3 Bioscience Receives FDA Clearance on Lead Product for Unmet Women’s Vaginal Health and Wellness Needs
Patented LivRing(TM) is an intravaginal ring that provides long-lasting, controlled release of moisture to supplement the body’s natural lubrication and enhance the ease and comfort of sexual activity. - October 27, 2021 - J3 Bioscience, Inc.
OmeCare and Hillsborough City School District Renew Partnership for Student and Faculty COVID-19 PCR Testing
Partnership helps district ensure safety standards and meet COVID-19 testing protocols for the 2021-2022 school year. - October 16, 2021 - OmeCare
Taysha Gene Therapies Adds Popular e-Learning Membership Program “The Lab Rascals Experience” by K-5 Edtech Company Club Lab Rascals to Employee Benefits Package
Club Lab Rascals, the nation’s #1 producer of culturally-inclusive K-5 STEM curricula, on-demand STEM camps and e-learning experiences, has partnered with Taysha Gene Therapies. Taysha is a biotech and patient-centric gene therapy company based in Dallas, TX. Taysha has elected Club Lab... - October 13, 2021 - Club Lab Rascals
Leyton Partners with the Massachusetts Biotechnology Council (MassBio®)
Leyton USA is excited to announce a partnership with the Massachusetts Biotechnology Council (MassBio®). Their combined efforts will help Biotech firms in New England take advantage of government tax incentives and promote innovation. Leyton is changing the way that the Bio-tech industry... - October 13, 2021 - Leyton
Thrombolex, Inc. – Interim Results of NIH-Funded RESCUE Trial
Thrombolex, Inc. – BASHIR™ Endovascular Catheter Shows Marked Reduction in RV/LV Ratio and Thrombus Burden in Patients with Acute Intermediate-Risk PE - October 06, 2021 - Thrombolex, Inc.
NY Imaging Specialists Brings the Future of Medical Imaging to Nassau County
NY Imaging Specialists today announced the opening of a brand-new comprehensive imaging center in Nassau County. The center includes advanced imaging technology, a women’s health center, an interventional radiology suite, and an adjoining New York Cancer & Blood Specialists medical... - October 04, 2021 - New York Imaging Specialists
Omni-HC Selected to Participate in “Audience Amplification” Workshop at Prestigious Global Medical Affairs Meeting
Omni Healthcare Communications has been selected by the Medical Affairs Professional Society to convene a workshop on scientific communication amplification at the MAPS 2022 Global Annual Meeting. - October 02, 2021 - Sunny Ayr Holdings
OmeCare and LifeSite Announce COVID-19 Testing Solution Partnership
The partnership provides a turnkey approach for workplaces, schools, major conventions and other group events looking to ensure safety and meet governmental mandates for students, staff, employees and event participants. - October 01, 2021 - OmeCare
Orange Neurosciences’ Digital Therapy Platform is Helping Neurodiverse Students Overcome Pandemic Challenges
A recent study by Stanford University states that reading skills have stalled among students due to school closures, with reading fluency in second and third graders reduced by 30 percent. Students with learning differences have had bigger challenges. ReadON, an affordable, non-pharmacological therapy, improves attention, focus and self-confidence, language barriers and more. - September 30, 2021 - Orange Neurosciences
WiCON Publishes the China Pharmaceutical Guide 2021 (16th Edition)
WiCON International Group LLC, the publisher of well-known WiCON | Pharma China (www.pharmachinaonline.com), announced that its China Pharmaceutical Guide 2021 (16th Edition) is now officially published. Now in its 16th edition, China Pharmaceutical Guide 2021 is thoroughly updated with the latest ample data from many reputable sources, abundant analysis by leading industry experts, new regulations and more case studies. - September 21, 2021 - WiCON International Group LLC
Clean-Label Micellar Water Formulation Banishes Trace Chemicals and Outperforms Leading Brand
Locus Performance Ingredients and Genomatica introduce sustainable, natural cleanser featuring Ferma® S sophorolipids and Brontide® natural butylene glycol that eliminates chemical additives and outperforms the current leading brand. The next-generation micellar water replaces controversial legacy ingredients with plant-derived ingredients that provide all the traditional micellar water benefits, but with superior functionality and sustainability. - September 11, 2021 - Locus Performance Ingredients
Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer
Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccine immunotherapy for cancer and infectious diseases where... - September 10, 2021 - Mirror Biologics, Inc.
Locus Performance Ingredients Launches New Biosurfactant-Based Personal Care Formulations to Ease Adoption of Clean Label Trend
Ready-to-use formulations utilizing novel Ferma® S sophorolipids help CPG companies replace commonly used surfactants, boost product performance and maximize sustainability. - September 09, 2021 - Locus Performance Ingredients
Scientists at AbboMax, Inc. Developed the New Panels of Monoclonal Antibodies to Study B- and T-Cell Lymphomas
Lymphoma is a malignant transformation of either B or T cells or their subtypes. All lymphoma subtypes combined are the seventh most common cancer in the United States. The B-cell lymphomas are types of lymphoma affecting B cells. About 85% of lymphomas are of B-cell origin. T-cell lymphomas are lymphomas that affect T cells. AbboMax has developed the new panels of monoclonal antibodies to study B- and T-cell lymphomas. - September 03, 2021 - AbboMax, Inc.
On-Body Biosensors: a Human Factors Development Approach
SMi Reports: Exploring therapeutic applications of connected on-body devices at Medical Wearables for Biosensors conference. - September 02, 2021 - SAE Media Group
Defined Bioscience Licenses FGF2-STAB (G3) for Use in Stem Cell Media
Defined recently concluded a licensing agreement with Czech Republic-based Enantis for global use of Enantis’ patented FGF2-STAB® technology both alone and in stem cell media formulations. FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using... - August 30, 2021 - Defined Bioscience Inc.
Neocortex Digital Announces Revolutionary Approach to Address Brain Functionality Connected to Vision
Neocortex Digitial is a new biotech startup with the vision of transforming new ways to address brain functionality connected to vision with the aim of providing early diagnosis and effective treatments for a range of vision and oculomotor dysfunctions. - August 25, 2021 - Neocortex Digital
Omni Healthcare Communications & Res Consortium Form Alliance to Expand Medical Affairs Capabilities
Omni Healthcare Communications (Omni-HC), a US based medical communications firm delivering solutions for today’s scientific exchange challenges, is pleased to announce the formation of a strategic alliance with Res Consortium (Res) of the United Kingdom, a cross-sector leader in digital... - August 21, 2021 - Sunny Ayr Holdings
Dr. Justice E. Obi Honored as a VIP Member for 2021 by Strathmore's Who's Who Worldwide Publication
Dr. Justice E. Obi of Brooklyn, New York has been honored as a VIP Member for 2021 by Strathmore’s Who’s Who Worldwide for his outstanding contributions and achievements in the fields of Biotechnology and pharmaceuticals. About Dr. Justice E. Obi Dr. Justice Obi is a doctor and... - August 18, 2021 - Strathmore Worldwide
Exclusive Interview with Alexander Stoll, Fresenius Kabi AB Speaker at SMi’s Aseptic Processing Conference
SMi Group reports: Hear from industry expert Alexandar Stoll, Frensenius Kabi AB on the latest updates in the Aseptic Processing field ahead of the conference this September. - August 06, 2021 - SAE Media Group